Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22576696 | 0.77 | CYP11B1 (0.35) | CYP11B1CYP11B2KCNN4MAPK1 | |
| SCHEMBL6046470 | 0.77 | KCNN4 (0.35) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL752388 | 0.77 | POLB (0.33) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL9137872 | 0.76 | SMN1; SMN2 (0.46) | POLBSMN1; SMN2MAPK1 | |
| SCHEMBL4638378 | 0.76 | SMN1; SMN2 (0.51) | POLBSMN1; SMN2MAPK1 | |
| SCHEMBL24033595 | 0.75 | POLB (0.35) | CYP11B1CYP11B2POLBSMN1; SMN2MAPK1 | |
| SCHEMBL1121836 | 0.74 | NOTUM (0.35) | CYP11B1CYP11B2POLBSMN1; SMN2 | |
| SCHEMBL24034152 | 0.74 | CYP1A2 (0.34) | CYP11B1CYP11B2POLBSMN1; SMN2 | |
| SCHEMBL10077140 | 0.74 | CYP1A2 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL30343520 | 0.74 | POLB (0.32) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081278-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2017-03-23 | — | — | US | disclosed |
| US-9540318-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9150508-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| EP-2760443-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR | Glaxo Group Limited (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013045431-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| WO-2010112865-A1 | 5-HT RECEPTOR MODULATING COMPOUNDS | SERODUS AS (NO) | 2010-10-07 | — | — | WO | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101312939-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006055462-A1 | 2-AMINO-4-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111338-A1 | 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
| CN-1471536-A | chemokine receptor antagonists and methods of use thereof | ǧ��ҩƷ��˾ | 2004-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP11B1 359/4885CYP11B2 881/4885POLB 380/4885 |
| US-20170081278-A1 | Novel compounds | RORC, RORB, RORA | CYP11B1 91/4885CYP11B2 125/4885POLB 4101/4885 |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORC, RORB | CYP11B1 299/4885CYP11B2 328/4885POLB 4141/4885 |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORB, RORC | CYP11B1 216/4885CYP11B2 304/4885POLB 4211/4885 |
| US-20060111338-A1 | 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | PYGM, PYGL, PYGB | CYP11B1 1445/4885CYP11B2 2144/4885POLB 1278/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP11B1 359/4885CYP11B2 881/4885POLB 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.